Flerie AB is set to hold an Extraordinary General Meeting on December 29, 2025, to approve a merger with Lipum AB, aimed at strengthening its market position in the biotechnology sector.
Target Information
Flerie AB, registered under the number 559067-6820, is a Swedish company seeking to announce its Extraordinary General Meeting scheduled for December 29, 2025. The meeting will be held at the Setterwalls Advokatbyrå offices located at Sturegatan 10, 114 36 Stockholm. Shareholders are encouraged to attend either in person or via postal voting prior to the meeting.
Industry Overview in Sweden
Sweden's economy is marked by a strong commitment to innovation and technology, particularly in the life sciences sector, where companies like Flerie operate. The Swedish pharmaceutical and biotechnology industries have shown robust growth, benefiting from significant governmental support and a highly educated workforce. The country is recognized internationally for its advancements in research and development, particularly in biomedicine.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Moreover, Sweden houses a vibrant ecosystem for startups and established companies alike, enabling collaboration and knowledge sharing. This environment fosters a culture of entrepreneurship,
Similar Deals
Novartis AG → Avidity Biosciences, Inc.
2026
Laborie Medical Technologies Corp. → JADA System
2026
Flerie AB
invested in
Lipum AB (publ)
in 2025
in a Merger deal